UMCU

Running trials

• Recruiting

  A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

  NCT07665450· Phase 3· Source

• Recruiting

  Dutch Registry of Pediatric Cardiac Arrest

  NCT06938009· Source

• Recruiting

  Prediction Models for Complications After CRT in Esophageal Cancer

  NCT06366828· Source

• Recruiting

  Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

  NCT04628026· Phase 3· Source

• Recruiting

  Aerobic Fitness or Muscle Mass Training to Improve Colorectal Cancer Outcome

  NCT04754672· Source

• Active, not recruiting

  Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer

  NCT03764553· Phase 2· Source

• Active, not recruiting

  Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT03399799· Phase 1· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute lymphoblastic leukaemia1 recruiting
• Acute myeloid leukemia1 recruiting
• Childhood cancers1 recruiting
• Colorectal cancer1 recruiting
• Gastric and esophageal cancer1 recruiting
• Multiple myeloma1 recruiting
• Myelodysplastic syndromes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Fractional Flow Reserve or 3D-Quantitative-Coronary-Angiography Based Vessel-FFR Guided Revascularization

  NCT04931771· Source

• Completed

  A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis

  NCT04131309· Phase 2· Source

• Completed

  Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

  NCT02950051· Phase 3· Source